Canada Ovarian Cancer Therapeutics Market Report 2023 to 2030

Canada Ovarian Cancer Therapeutics Market Analysis

$ 3999

Canada Ovarian Cancer Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors driving the growth of the ovarian cancer market is the rising prevalence of the disease. Other important drivers are the development of new therapies and treatments, rising healthcare expenses, and increased government support. Due to greater public awareness of healthcare issues, the market for ovarian cancer is also expanding. Major global players in Ovarian Cancer Therapeutics Market are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc., Exelixis, Inc., KINTARA THERAPEUTIC, INC., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Private Limited, AbbVie Inc.

ID: IN10CARD056 CATEGORY: Rare Diseases GEOGRAPHY: Canada AUTHOR: Sakshi Mantri

Buy Now

Canada Ovarian Cancer Therapeutics Market Analysis Summary

Canada Ovarian Cancer Therapeutics Market is valued at around $0.16 Bn in 2022 and is projected to reach $0.24 Bn by 2030, exhibiting a CAGR of 5.4% during the forecast period 2023-2030.

Ovarian cancer is a type of malignant disease that develops aberrant cell growth in the tissues of the epithelium, or outer, lining of the ovaries and fallopian tubes. Women's ovarian cancer is brought on by a variety of factors, such as mutations in the BRCA1 and BRCA2 genes and a family history of the condition. It commonly develops without any symptoms in the early stages and is discovered at an advanced stage. Ovarian cancer is normally treated surgically, with additional medicines frequently added later. Ovarian cancer is more likely to strike older women and those with a family history of cancers of the reproductive system.

Along with other factors like advancements in cancer therapies and other fields, an increase in the proportion of elderly women, the ease of use of new drugs and therapies, an increase in healthcare spending, and increased government funding, it is anticipated that ovarian cancer will become more common. The numerous government and non-government initiatives undertaken for ovarian cancer research and investment further extend favourable opportunities for the expansion of the ovarian cancer medicine market in the near future.

Major global players in Ovarian Cancer Therapeutics Market are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc., Exelixis, Inc., KINTARA THERAPEUTIC, INC., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Private Limited, AbbVie Inc.

Market Dynamics

Market Drivers

the increase in the number of elderly women

Ovarian cancer risk is increasing due to the rising population of elderly women. This population increase may have an impact on the market for ovarian cancer medications.

Growing consumer knowledge of healthcare is propelling the market.

Growing public health consciousness has led to predictions that the markets for the medications bevacizumab (Avastin) and pazopanib (Votrient) will grow. The pharma market is anticipated to profit simultaneously from advancements in ovarian cancer treatments. Various studies on ovarian cancer treatments are ongoing, and some of those that are now being tested may soon be available on the market.

Expiring patents encourage new market entrants

Patents held by previous corporations coming to an end can benefit newly emerging enterprises. The utilisation of cutting-edge combination therapies as a form of treatment is a significant factor in the growth of the ovarian cancer pharmaceutical sector. Research and development investment from the public and private sectors is a market contribution.

Market Developments

November 2022: The acquisition of Gateway Genomics, LLC by Myriad Genetics Inc. The acquisition strengthens Myriad Genetics' portfolio of women's health products by increasing access to personalised genetic diagnostics for women both throughout and beyond the reproductive stage of life. By helping expectant women early with SneakPeek and offering data-driven genetic insights throughout their lives with the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Score for All Ancestries, Myriad will see an increase in revenue.

In October 2022: Quest Diagnostics and Decode Health developed RNA (transcriptome) sequencing capabilities as part of a new phase of their collaboration based on their respective next-generation sequencing, analytics, and clinical expertise. Because biomarker-based data can speed up and lower the cost of developing new diagnostic tests and locating novel therapy targets for various cancers, the relationship is crucial (breast, prostate and ovarian cancer). This collaboration increases the company's visibility on a worldwide scale and helps it explore new R&D opportunities.

Key players

AbbVie Inc Amgen Inc AstraZeneca PLC Bristol-Myers Squibb Co Celgene Corporation Clovis Oncology Inc Eisai Co Ltd Genentech Inc Johnson & Johnson Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Canada Ovarian Cancer Therapeutics Market

By Cancer Type

Epithelial Ovarian Tumors
Ovarian Germ Cell Tumors
Other Cancer Types

By Therapeutics

Chemotherapy
Radiation Therapy
Immunotherapy
Hormonal Therapy
Other Therapeutics

By End User

Hospitals
Research Institutes
Specialty Clinics

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.